These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34718690)

  • 21. Margin width and local recurrence after breast conserving surgery for ductal carcinoma in situ.
    Ekatah GE; Turnbull AK; Arthur LM; Thomas J; Dodds C; Dixon JM
    Eur J Surg Oncol; 2017 Nov; 43(11):2029-2035. PubMed ID: 28917445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ductal carcinoma in situ--the influence of the radiotherapy boost on local control.
    Wong P; Lambert C; Agnihotram RV; David M; Duclos M; Freeman CR
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e153-8. PubMed ID: 21664063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities.
    Perez CA
    Cancer J; 2003; 9(6):442-53. PubMed ID: 14740972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.
    Monteau A; Sigal-Zafrani B; Kirova YM; Fourchotte V; Bollet MA; Vincent-Salomon A; Asselain B; Salmon RJ; Fourquet A
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1021-8. PubMed ID: 19386441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: A multi-center study and population-based analysis.
    Jobsen JJ; Scheijmans LJEE; Smit WGJM; Stenfert Kroese MC; Struikmans H; van der Palen J
    Breast; 2018 Dec; 42():3-9. PubMed ID: 30118902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
    Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
    BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No Ink on Ductal Carcinoma
    Fregatti P; Gipponi M; Depaoli F; Murelli F; Guenzi M; Bonzano E; Ceppi M; Friedman D
    Anticancer Res; 2019 Jan; 39(1):459-466. PubMed ID: 30591495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypofractionated radiation therapy for breast ductal carcinoma in situ.
    Hathout L; Hijal T; Théberge V; Fortin B; Vulpe H; Hogue JC; Lambert C; Bahig H; Provencher L; Vavassis P; Yassa M
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1058-63. PubMed ID: 24113057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04).
    Kim JH; Choi DH; Park W; Ahn SD; Kim SS; Ha SW; Kim K; Kim YB; Yea JW; Kang MK; Shin KH; Kim DW; Lee JH; Suh CO
    Breast Cancer Res Treat; 2014 Jul; 146(2):341-5. PubMed ID: 24939061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
    Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailored radiation dose according to margin width for patients with ductal carcinoma in situ after breast-conserving surgery.
    Kim H; Kim TG; Park B; Kim J; Jun SY; Lee JH; Choi HJ; Jung CS; Lee HW; Lee JS; Nam HY; Shin S; Kim SM; Kim H
    Sci Rep; 2024 Jan; 14(1):300. PubMed ID: 38168758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does a Close Surgical Margin for Ductal Carcinoma In Situ Associated with Invasive Breast Carcinoma Affect Breast Cancer Recurrence?
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2020 Aug; 33(7):627-633. PubMed ID: 32643476
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.
    Rivera R; Banks A; Casillas-Lopez A; Rashtian A; Lewinsky B; Sheth P; Hovannesian-Larsen L; Brousseau D; Iyengar G; Holmes DR
    Breast J; 2016; 22(1):63-74. PubMed ID: 26534876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Importance of Surgical Margin Status in Ductal Carcinoma In Situ.
    Shaikh T; Li T; Murphy CT; Zaorsky NG; Bleicher RJ; Sigurdson ER; Carlson R; Hayes SB; Anderson P
    Clin Breast Cancer; 2016 Aug; 16(4):312-8. PubMed ID: 26952595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
    Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy.
    Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
    Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study).
    De Rose F; De Santis MC; Meduri B; Franzese C; Franceschini D; Franco P; Pasinetti N; Lancellotta V; Giacobazzi P; La Rocca E; D'Angelo E; Lozza L; Livi L; Meattini I; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2069-2077. PubMed ID: 33387035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.